Skyhawk Therapeutics entered a collaborative agreement with Merck KGaA focused on discovering small-molecule RNA splicing modulators for neurological diseases. The deal, valued up to $2 billion, will utilize Skyhawk’s SkySTAR platform to identify candidates targeting RNA involved in challenging neurological indications. Skyhawk will lead early discovery with Merck KGaA having subsequent development and commercialization options. This partnership represents a significant investment in RNA-targeted therapies aiming to address undruggable targets beyond cell surface proteins.